跳至主要内容
临床试验/NCT01999374
NCT01999374招募中不适用

Long Term Follow up of Recipients of Functional Islet Allografts

Rodolfo Alejandro1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2013年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
30
试验地点
1
主要终点
Duration of sustained islet allograft function

研究概览

简要总结

Since its inception, the Diabetes Research Institute (DRI) has made significant contributions to the field of diabetes, pioneering many of the techniques used in diabetes centers around the world. Through several clinical trials, DRI has demonstrated that diabetes can be successfully reversed as a result of islet cell transplant.

Over the years the following protocols in islet cell transplantation have been initiated: 2000/0329; 2000/0196; 2004/0205; 2000/024; 2006/0200; 2006/0508; 2006/0210.

All of the studies listed above will be source of study subjects for this study. Approximately 30 subjects are expected to be enrolled and followed in this trial.

After islet-cell transplantation in the parent studies, each subject receives maintenance immunosuppressive medications.

The purpose of this protocol is to collect additional follow-up for safety and efficacy from subjects with graft function after their completion in their parent study. It is expected that most subjects will retain measurable islet function and, in the islet-alone studies, continue to receive immunosuppressive medications at the time of completing their parent study.

详细描述

To provide long term follow up in subjects with functional islet allografts.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Participation in any of the following parent studies: 2000/0329; 2000/0196; 2004/0205; 2000/0024; 2006/0200; 2006/0508; 2006/0210
  • •A functioning pancreatic islet graft (absence of graft failure as defined in parent study) requiring immunosuppression.
  • •Willingness of participants to continue to use an approved method of contraception during and 4 months after study participation.
  • •Ability to provide written informed consent.

排除标准

  • •For female subjects: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable.
  • •Any medical condition that, in the opinion of the investigator, will interfere with safe participation in the trial.

结局指标

主要结局

Duration of sustained islet allograft function

时间窗: 3 years

The primary endpoint is duration of sustained islet allograft function as determined by evidence from Mixed Meal Tolerance Test of c-peptide production. A c-peptide level \>=0.3 ng/ml at 0, 60, or 90 minutes will be considered evidence of islet allograft function.

次要结局

未报告次要终点

研究者

发起方
Rodolfo Alejandro
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Rodolfo Alejandro

Professor of Medicine

University of Miami

研究点 (1)

Loading locations...

相似试验